Mit Family Translocation Renal Cell Carcinoma has emerging NIH research funding with 3 grants totaling $2.7M.
NIH fiscal year (Oct–Sep)
Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Mit Family Translocation Renal Cell Carcinoma. Strongest funded area: Translational / Drug Development. Largest gap: Epidemiology / Natural History.
2 funded grants in Translational / Drug Development but only 1 related publication found for MIT family translocation renal cell carcinoma. This may indicate early-stage research that hasn't yet produced published results.
10 publications in Case Report / Case Series but no NIH-funded grants found in Epidemiology / Natural History for MIT family translocation renal cell carcinoma. Existing research activity suggests this may be a viable area for grant applications.
Track funding opportunities for Mit Family Translocation Renal Cell Carcinoma.
Follow this disease to be notified about new NIH grants and funding changes.
Already have an account? Sign in to manage your watchlists.